TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03654040

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: arTreg
Description: Eligible participants will receive a single dose of Treg product (arTreg). The target dose is at least 90 x 10\^6 total cells.~Method of receipt: peripheral intravenous (IV) infusion, administered over 20 to 30 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis
Description: Leukapheresis will be the method employed to recover peripheral blood mononuclear cells (PBMCs) from the allograft recipient. The recipient will undergo the procedure prior to initiating the cyclophosphamide conditioning regimen.~Procedure on Day -3 (-1 day) prior to Treg product (arTreg) IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 40 mg/kg administered intravenously (IV) following leukapheresis and between 1 to 3 days prior to Treg product (arTreg) infusion, per institutional standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: Mesna is administered:~* Intravenously to inhibit hemorrhagic cystitis induced by cyclophosphamide, and~* In conjunction with the cyclophosphamide, per institutional practice with CTX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: EVR is approved for prophylaxis of allograft rejection in adults receiving a liver transplant. Per protocol: Post transplantation, subject will initially receive standard IS with tacrolimus (TAC),plus a mycophenolate product and/or steroids.Subsequently, evaluation for eligibility to be converted to EVR-based IS regimen will occur and, when applicable, proceed. Once the optimal EVR trough level is achieved,TAC dose will be reduced. When target EVR and TAC levels are maintained over two consecutive measurements, ALT liver function test (LFT) is ≤50 U/L, GGT LFT is ≤ the upper limit of normal or ≤ 1.5 times the baseline GGT, subject will be considered successfully converted to EVR-based IS regimen. EVR doses will be administered/monitored/adjusted over time.
Study: NCT06230003

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ultrasound guided ESP block either with the local anesthetic of 0.5% of Ropivicane 20 mL bilaterally (intervention group) or normal saline (control group) before surgery which will take 5-10 minutes in a 1:1 ratio.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Ultrasound guided bilateral ESP block either with normal saline
Study: NCT06517641

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haploidentical donor bone marrow transplant
Description: Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive a haploidentical donor bone marrow transplant.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unrelated donor bone marrow transplant
Description: Drugs:~1. Antithymocyte Globulin (ATG) dose will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.~2. Fludarabine dose will be 30 mg/m\^2 IV daily for 5 days from Day -6 to Day -2.~3. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation.~4. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL.~5. Mycophenolate mofetil (MMF) dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 through Day +35.~6. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is \> 1500 for 3 days.~Radiation:~1. Total Body Irradiation (TBI): will be given as a single dose of 400 cGy on Day -1.~Procedure:~1. HSCT: Eligible patients will receive an unrelated donor bone marrow transplant.
Study: NCT05871658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: electroacupuncture
Description: electroacupuncture were inserted into bilateral Zusanli (ST36), Sanyinjiao (SP6), Hegu (LI4) and Quchi (LI11), and Yintang (EX-HN3). Electroacupuncture parameters selected the sparse wave, the frequency was 4 Hz, the stimulation intensity was tolerated by the patient.
Study: NCT04842786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Coconut oil, Parachute oil composition: 92% lauric (C12) fatty acid, 6% oleic fatty acid, 2% linoleic fatty acid
Study: NCT05600465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation + Occupational Therapy
Description: In the BA-OT Approach, the PI will use an evidence-based 4-step process (Goal-Plan-Do-Check) to assist the older adults to develop strategies to plan and execute daily health self-management activities. BA-OT teaches older adults with MCC and functional limitations to 1) set achievable and meaningful activity goals, 2) engage in action planning that includes brainstorming strategies to overcome barriers, 3) evaluate the results after performing the activity, and 4) to modify the plan or choose a new goal, then generalize strategies to new problems. By assisting participants to develop daily routines and integrate safe health self-management activities into these routines, occupational therapists are providing strategies that support adaptation in the face of stressful situations.. Goal examples may include adapting and scheduling exercise plans, or exploring assistive devices and strategies for safe and healthy meal preparation.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Fitbit, 1 hour training, handout on managing chronic conditions
Study: NCT06329752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Sciatic Nerve block (20 mL of 2% Lidocaine)
Description: Patients will be scanned with the ultrasound machine to determine the technical feasibility of sciatic nerve blocks. If feasible, one of the following techniques will be performed a) popliteal sciatic nerve block, with either lateral or posterior approach; b) CAPS (crosswise approach to popliteal sciatic) block, with either lateral to medial or anterolateral to posteromedial approach; c) subgluteal sciatic nerve block; d) transgluteal sciatic nerve block. In all cases, 20 mL of 2% Lidocaine will be used.
Study: NCT05186363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemopreventive Agent - SPAQ
Description: Seasonal malaria chemoprevention (SMC) is a highly effective community-based intervention to prevent malaria infections in areas where the malaria burden is high and transmission occurs mainly during the rainy season. It involves administering monthly courses of sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) during this peak transmission period to those most at risk: children 3-59 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Test - no drugs given
Description: This is where children aged 3-59 months do not receive any chemoprevention drugs but do receive health promotion messages and visit from health workers similar to the chemoprevention SPAQ arm.
Study: NCT05445921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: The stellate ganglion will be identified using ultrasound guidance, and after a test does of 1% lidocaine, 1% mepivacaine will be injected near the stellate ganglion.
Study: NCT05281237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AveCure 16 Gauge Flexible Microwave Ablation Probe
Description: Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery
Study: NCT05628285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentio 1
Description: Sound processor
Study: NCT06196658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-EX02 CAR T cells
Description: Conditioning chemotherapy:~• Lymphodepletion regimen consisting of fludarabine 25 mg/m2/day and cyclophosphamide 250 mg/m2/day for 3 consecutive days, administered 48 hours before first administration of first time of intravenous or intraperitoneal infusion~Investigational Product:~• Regional administration: Acetaminophen 500mg orally and diphenhydramine 20mg intramuscularly (or other non-steroidal anti-inflammatory drugs and antihistamines) were given in advance on the day of administration (day 0). Intraperitoneal infusion or intra-tumoral injection of anti-EX02 CAR T cells, with dosage and method determined by the investigator~• Intravenous administration: Single infusion of CAR-transduced autologous T cells administered intravenously at a target dose of 2 x 106 anti-EX02 CAR T cells/kg, 30 minutes after premedication with oral acetaminophen 500mg and intramuscular diphenhydramine 20mg
Study: NCT04934696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986166
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral contraceptive
Description: Specified dose on specified days
Study: NCT06329466

Intervention type: OTHER
Intervention: intervention (EFT) group
Description: It is the group to which EFT is applied.

Intervention type: OTHER
Intervention: intervention (EFT) group
Description: It is the group to which EFT is applied.
Study: NCT04770428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI7352
Description: A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
Study: NCT05774574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) supplementation
Description: Daily supplementation with 1 ml hemp oil containing 60 mg CBD, applied orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplementation
Description: Daily supplementation with 1 ml hemp oil containing 0 mg CBD, applied orally
Study: NCT05141344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 3 MG Oral Tablet
Description: it will be given orally one hour preoperatively

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar-coated tablets will be given one hour preoperatively
Study: NCT06491992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Phonophresis
Description: Chitosan Phonophresis, three times per week for four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy exercise
Description: selected neck exercise and electrotherapy on cervical region

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy exercise
Description: selected neck exercise and electrotherapy on cervical region
Study: NCT05203744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine prophylaxis
Description: The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine prophylaxis
Description: The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine prophylaxis
Description: The study will be conducted in three parts with 200 participants invited to participate in the study.~* Part 1 consist of 200 participants to be administered a loading dose of 600 mg tafenoquine (200 mg daily for 3 days) followed by 200 mg weekly for two weeks.~* Part 2: The same participants from Part 1 will be administered a monthly dose of tafenoquine (600 mg total, given as 300 mg split over 2 days) for two consecutive months. This monthly dose of 600 mg tafenoquine is designated the low monthly tafenoquine dose.~* Part 3: The same participants from Parts 1 and 2 will be administered a monthly dose of tafenoquine (800 mg total, given as 400 mg split over 2 days) for two consecutive months. This monthly dose of 800 mg tafenoquine is designated the high monthly tafenoquine dose.
Study: NCT06479512

Intervention type: DEVICE
Intervention: ultrasonography to measure the index of the caval aorta and non-invasive pulse oximetry for perfusion index
Description: Inferior vena cava and aortic diameter measurements will be made by ultrasonography and perfusion index determination using non-invasive pulse oximetry
Study: NCT05682859

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast 500 Mcg Oral Tablet
Description: Randomized to either systemic roflumilast or placebo in phase 1. All participating patients will receive roflumilast in phase 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT06060379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GiochiAMO a 626
Description: The subjects of the intervention group will play three different games: a role-playing game, a card game and a board game.
Study: NCT05805215

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non-invasive Temporal Interference stimulation and Face-name association training task targeting the hippocampus
Description: TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Non-invasive Temporal Interference stimulation and Face-name association training task targeting the Precuneus
Description: TIS relies on high frequencies which can penetrate with relatively low loss. High-frequency carriers (\>1 kHz) emitted by two (or more) pairs of cutaneous electrodes can temporally interfere at deep peripheral nerve targets. The effective stimulation frequency is equal to the offset frequency between the carriers. By controlling field orientation and frequency offset, the hot spot of constructive interference can be precisely targeted. The key aspect of this method is the use of carrier waves at frequencies higher than 1 kHz. Frequencies above this range are regarded as non-stimulating and pass-through tissues with relatively low loss. While these higher frequencies do not stimulate neural tissue, the interference envelope of two phase-shifted frequencies can elicit action potentials because the offset (aka beat) frequency can be tuned accordingly to \< 100 Hz.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: High-frequency stimulation (placebo) with Face-name association training task
Description: High-frequency (\>1 kHz) stimulation; Standardly used as a carrier frequency; Effects are expected to he high-pass filtered by neurons
Study: NCT06029179

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium zirconium cyclosilicate (SZC)
Description: 40 patients will receive sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days (15 gm/week) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium polystyrene sulfonate
Description: 40 patients will receive sodium polystyrene sulfonate 15 g once daily on non-dialysis days (45 gm/week) for 8 weeks.
Study: NCT04712981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE
Description: Peer leaders/role models will be trained in HOPE intervention fundamentals and assigned to online community groups with participants.
Study: NCT06079346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OT-101
Description: OT-101: antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid (mRNA) of the human TGF-β2 gene

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Folinic acid, 5-FU, Irinotecan, Oxaliplatin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFIRINOX
Description: Folinic acid, 5-FU, Irinotecan, Oxaliplatin
Study: NCT05079581

Intervention type: OTHER
Group type: OTHER
Intervention: Pelvic floor exercises
Description: The participants in the intervention group will be taught exercises involving strengthening the muscles around the pelvic floor in sitting, standing and lying positions by a physiotherapist who has been trained in women's health for 4 years and will be asked to perform them as home exercises every day for 8 weeks. The exercises are as follows:~They will be asked to tighten the muscles around the urethra, vagina and rectum as hard as possible, upwards and inwards (from the bottom up) and hold it in this way for 8-10 seconds. It will be applied in different positions as in the table.
Study: NCT06180616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide will be self-administered subcutaneously by study participants via an injection. The drug will be taken weekly following the schedule: 4 weeks at 2.5 mg QW, 4 weeks at 5.0 mg QW, 4 weeks at 7.5 mg QW, 4 weeks at 10.0 mg QW, 4 weeks at 12.5 mg QW, 12 weeks at 15 mg QW.~Modification of study drug will be performed if the participant is experiencing significant side effects and cannot tolerate the higher dosage of the study drug. In this instance, the study drug dosage will be reduced to the previously tolerated dosage and held at this dose for a further 4 weeks. One further attempt at dose escalation will be undertaken after 4 weeks, at the discretion of the participant and the study investigator. If recurrent side effects are experienced by the participant, the study drug will be returned to the previously tolerated dosage, and the prescription continued at this dosage for the remainder of the study.